Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86


The characterization of a novel monoclonal antibody against CD93 unveils a new antiangiogenic target.

Orlandini M, Galvagni F, Bardelli M, Rocchigiani M, Lentucci C, Anselmi F, Zippo A, Bini L, Oliviero S.

Oncotarget. 2014 May 15;5(9):2750-60.


CD93 and dystroglycan cooperation in human endothelial cell adhesion and migration adhesion and migration.

Galvagni F, Nardi F, Maida M, Bernardini G, Vannuccini S, Petraglia F, Santucci A, Orlandini M.

Oncotarget. 2016 Mar 1;7(9):10090-103. doi: 10.18632/oncotarget.7136.


Elevated expression of the C-type lectin CD93 in the glioblastoma vasculature regulates cytoskeletal rearrangements that enhance vessel function and reduce host survival.

Langenkamp E, Zhang L, Lugano R, Huang H, Elhassan TE, Georganaki M, Bazzar W, Lööf J, Trendelenburg G, Essand M, Pontén F, Smits A, Dimberg A.

Cancer Res. 2015 Nov 1;75(21):4504-16. doi: 10.1158/0008-5472.CAN-14-3636. Epub 2015 Sep 11.


Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.

Huang SW, Lien JC, Kuo SC, Huang TF.

Carcinogenesis. 2012 May;33(5):1022-30. doi: 10.1093/carcin/bgs127. Epub 2012 Mar 20.


The epidermal growth factor-like domain of CD93 is a potent angiogenic factor.

Kao YC, Jiang SJ, Pan WA, Wang KC, Chen PK, Wei HJ, Chen WS, Chang BI, Shi GY, Wu HL.

PLoS One. 2012;7(12):e51647. doi: 10.1371/journal.pone.0051647. Epub 2012 Dec 18.


Elevated expression of CD93 promotes angiogenesis and tumor growth in nasopharyngeal carcinoma.

Bao L, Tang M, Zhang Q, You B, Shan Y, Shi S, Li L, Hu S, You Y.

Biochem Biophys Res Commun. 2016 Aug 5;476(4):467-474. doi: 10.1016/j.bbrc.2016.05.146. Epub 2016 May 30.


Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.

Liu YR, Guan YY, Luan X, Lu Q, Wang C, Liu HJ, Gao YG, Yang SC, Dong X, Chen HZ, Fang C.

Biomaterials. 2015 Feb;42:161-71. doi: 10.1016/j.biomaterials.2014.11.039. Epub 2014 Dec 16.


A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth.

Yan X, Lin Y, Yang D, Shen Y, Yuan M, Zhang Z, Li P, Xia H, Li L, Luo D, Liu Q, Mann K, Bader BL.

Blood. 2003 Jul 1;102(1):184-91. Epub 2003 Feb 27.


Antiangiogenesis agents avastin and erbitux enhance the efficacy of photodynamic therapy in a murine bladder tumor model.

Bhuvaneswari R, Yuen GY, Chee SK, Olivo M.

Lasers Surg Med. 2011 Sep;43(7):651-62. doi: 10.1002/lsm.21109.


Dual targeting of the type 1 insulin-like growth factor receptor and its ligands as an effective antiangiogenic strategy.

Bid HK, London CA, Gao J, Zhong H, Hollingsworth RE, Fernandez S, Mo X, Houghton PJ.

Clin Cancer Res. 2013 Jun 1;19(11):2984-94. doi: 10.1158/1078-0432.CCR-12-2008. Epub 2013 Apr 2.


Multimerin-2 is a ligand for group 14 family C-type lectins CLEC14A, CD93 and CD248 spanning the endothelial pericyte interface.

Khan KA, Naylor AJ, Khan A, Noy PJ, Mambretti M, Lodhia P, Athwal J, Korzystka A, Buckley CD, Willcox BE, Mohammed F, Bicknell R.

Oncogene. 2017 Nov 2;36(44):6097-6108. doi: 10.1038/onc.2017.214. Epub 2017 Jul 3.


Orally Administered Mucolytic Drug l-Carbocisteine Inhibits Angiogenesis and Tumor Growth in Mice.

Shinya T, Yokota T, Nakayama S, Oki S, Mutoh J, Takahashi S, Sato K.

J Pharmacol Exp Ther. 2015 Sep;354(3):269-78. doi: 10.1124/jpet.115.224816. Epub 2015 Jun 30.


Anti-Gb3 monoclonal antibody inhibits angiogenesis and tumor development.

Desselle A, Chaumette T, Gaugler MH, Cochonneau D, Fleurence J, Dubois N, Hulin P, Aubry J, Birklé S, Paris F.

PLoS One. 2012;7(11):e45423. doi: 10.1371/journal.pone.0045423. Epub 2012 Nov 26.


Blocking FGF2 with a new specific monoclonal antibody impairs angiogenesis and experimental metastatic melanoma, suggesting a potential role in adjuvant settings.

de Aguiar RB, Parise CB, Souza CR, Braggion C, Quintilio W, Moro AM, Navarro Marques FL, Buchpiguel CA, Chammas R, de Moraes JZ.

Cancer Lett. 2016 Feb 28;371(2):151-60. doi: 10.1016/j.canlet.2015.11.030. Epub 2015 Dec 3.


Fisetin inhibits various attributes of angiogenesis in vitro and in vivo--implications for angioprevention.

Bhat TA, Nambiar D, Pal A, Agarwal R, Singh RP.

Carcinogenesis. 2012 Feb;33(2):385-93. doi: 10.1093/carcin/bgr282. Epub 2011 Dec 1.


Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.

Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, Salumbides B, Sanni T, Atadja P, Pili R.

Clin Cancer Res. 2006 Jan 15;12(2):634-42.


Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.

Bruns CJ, Liu W, Davis DW, Shaheen RM, McConkey DJ, Wilson MR, Bucana CD, Hicklin DJ, Ellis LM.

Cancer. 2000 Aug 1;89(3):488-99.


FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.

Gao W, Jin K, Lan H, Han N, Cao F, Teng L.

Hepatogastroenterology. 2012 Nov-Dec;59(120):2543-7.


Mimotope vaccination for epitope-specific induction of anti-VEGF antibodies.

Li W, Ran Y, Li M, Zhang K, Qin X, Xue X, Zhang C, Hao Q, Zhang W, Zhang Y.

BMC Biotechnol. 2013 Sep 27;13:77. doi: 10.1186/1472-6750-13-77.


Anti-angiogenic quassinoid-rich fraction from Eurycoma longifolia modulates endothelial cell function.

Al-Salahi OS, Kit-Lam C, Majid AM, Al-Suede FS, Mohammed Saghir SA, Abdullah WZ, Ahamed MB, Yusoff NM.

Microvasc Res. 2013 Nov;90:30-9. doi: 10.1016/j.mvr.2013.07.007. Epub 2013 Jul 27.


Supplemental Content

Support Center